Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.

Completed · Phase 4

Conditions studied: Skin Infections, Bacterial

In brief

A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or impetigo (bullous and non-bullous).

Key facts

Study ID

NCT00555061

Run by

GlaxoSmithKline

People needed

60

Starts

2007-09-01

Expected to finish

2008-08-01

Last updated by the study team

2016-12-28

Who can join

Age: 0 and older, up to 2. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject Age: The subject is ≥2 months to ≤24 months of age at study entry
• Subject Diagnosis: The subject has a diagnosis of secondarily-infected traumatic lesion (SITL), secondarily-infected dermatoses (SID), or primary impetigo (bullous or non-bullous) that is suitable for treatment with topical antibacterial therapy:
• The subject has a small laceration, sutured wound or abrasion, which has a secondary bacterial infection. The infected portion of the laceration or sutured wound should not exceed 10cm in length with surrounding erythema not extending more than 2cm from the edge of the wound. Abrasions should not exceed 2% of the total body surface area with surrounding erythema not extending more than 2cm from the edge of the abrasion.
• The subject has a diagnosis of inflammatory skin disease (i.e., dermatosis), such as atopic dermatitis or contact dermatitis, which has a secondary bacterial infection. The infected portion of the lesion(s) should not exceed 2% of the total body surface area.
• Impetigo: The subject has a lesion or group of £10 discrete localized lesions on otherwise healthy skin, characterized by red spots or blisters without crusts which later progress to lesions which ooze and form yellow or honey-colored crusts surrounded by an erythematous margin.
• Subject SIRS Score: The subject has a total SIRS score of at least 8 (Appendix 1 Skin Infection Rating Scale)
• Protocol Compliance: The parent/legal guardian is willing to comply with the protocol
• Informed Consent: The parent/legal guardian has given written informed, dated consent for the subject to participate in the study
• French Subjects: In France, a subject will be eligible for inclusion in this study if either affiliated to or a beneficiary of a social security category

You may not qualify if…

• The subject has demonstrated a previous hypersensitivity reaction to pleuromutilin or any component of the ointment (refer to the Investigator Brochure for composition of Retapamulin ointment, 1%)
• The subject was considered to be premature at birth (<37 weeks gestation)
• The subject has a secondarily-infected animal/human bite, or a puncture wound
• The subject has an abscess
• The subject has a chronic ulcerative lesion that is unlikely to have Staphylococcus aureus or Streptococcus pyogenes as the causative agent
• The subject has systemic signs and symptoms of infection (such as fever; defined as a temperature equivalent to a rectal temperature greater than 101°F or 38.3°C)
• The subject has a bacterial skin infection which, due to area, depth or severity, in the opinion of the investigator, cannot be appropriately treated by a topical antibiotic
• The subject has more than one type of infected lesion as defined in the protocol
• The subject requires surgical intervention for treatment of the infection prior to enrollment in the study, or is likely to require such intervention during the course of the study
• The subject has applied any topical therapeutic agent (including glucocorticoid steroids, antibacterials or antifungals) directly to the infected wound/lesion, within 24 hours prior to study entry
• The subject has received one or more days of treatment with a systemic antibacterial within 72 hours of study entry
• The subject is receiving systemic corticosteroids at a dose of >0.125mg/kg per day of prednisone (or the equivalent)
• The subject has a known, pre-existing, serious underlying disease that could be imminently life-threatening
• The subject has participated in any study using an investigational drug during the previous 30 days prior to entering the study
• The subject has been previously enrolled in this study or in any other study involving Retapamulin

Where it is running

• GSK Investigational Site — Tuscaloosa, Alabama, United States
• GSK Investigational Site — Bentonville, Arkansas, United States
• GSK Investigational Site — Orange, California, United States
• GSK Investigational Site — Woburn, Massachusetts, United States
• GSK Investigational Site — Cleveland, Ohio, United States
• GSK Investigational Site — Houston, Texas, United States
• GSK Investigational Site — Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
• GSK Investigational Site — Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
• GSK Investigational Site — Santiago, Región Metro de Santiago, Chile
• GSK Investigational Site — San José, Costa Rica
• GSK Investigational Site — Nördlingen, Bavaria, Germany
• GSK Investigational Site — Bochum, North Rhine-Westphalia, Germany
• GSK Investigational Site — Erkrath, North Rhine-Westphalia, Germany
• GSK Investigational Site — Goch, North Rhine-Westphalia, Germany
• GSK Investigational Site — Kleve-Materborn, North Rhine-Westphalia, Germany
• GSK Investigational Site — México, Mexico
• GSK Investigational Site — Alphen aan den Rijn, Netherlands
• GSK Investigational Site — Losser, Netherlands
• GSK Investigational Site — Roelofarendsveen, Netherlands
• GSK Investigational Site — Rotterdam, Netherlands
• GSK Investigational Site — Soerendonk, Netherlands
• GSK Investigational Site — Woerden, Netherlands
• GSK Investigational Site — Benoni, South Africa
• GSK Investigational Site — Newtown, South Africa
• GSK Investigational Site — Taipei, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.